Patients with minimal assurance (patients who have received minimal assurance 12 months after being issued by the Civil Affairs Bureau) can be given Creda _ (pabolizumab injection) with a maximum dose of 24 months after being approved by the Foundation.
Conditions of assistance:
1. medical conditions: patients who meet the indications of Creda _ (pabolizumab injection) in China.
(1) Patients with stage ⅳ melanoma diagnosed by pathology (histology or cytology) or patients with stage ⅲ melanoma who cannot receive radical treatment.
(2) It must be a patient with advanced melanoma who has received first-line treatment.
(3) Patients are generally suitable for tumor immunotherapy.
2. Economic conditions: Due to family economic reasons, the patient cannot afford the follow-up treatment expenses of Creda _ (Pabolizumab Injection).